- Home
- SPHL vs MBIO Comparison
SPHL vs MBIO Comparison
Compare SPHL & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHL
- MBIO
- Stock Information
- Founded
- SPHL 2002
- MBIO 2015
- Country
- SPHL Singapore
- MBIO United States
- Employees
- SPHL N/A
- MBIO N/A
- Industry
- SPHL Homebuilding
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- SPHL Consumer Discretionary
- MBIO Health Care
- Exchange
- SPHL Nasdaq
- MBIO Nasdaq
- Market Cap
- SPHL 4.9M
- MBIO 4.7M
- IPO Year
- SPHL 2024
- MBIO N/A
- Fundamental
- Price
- SPHL $0.65
- MBIO $1.47
- Analyst Decision
- SPHL
- MBIO
- Analyst Count
- SPHL 0
- MBIO 0
- Target Price
- SPHL N/A
- MBIO N/A
- AVG Volume (30 Days)
- SPHL 2.3M
- MBIO 127.7K
- Earning Date
- SPHL 12-29-2025
- MBIO 11-12-2025
- Dividend Yield
- SPHL N/A
- MBIO N/A
- EPS Growth
- SPHL N/A
- MBIO N/A
- EPS
- SPHL N/A
- MBIO N/A
- Revenue
- SPHL $5,956,226.00
- MBIO N/A
- Revenue This Year
- SPHL N/A
- MBIO N/A
- Revenue Next Year
- SPHL N/A
- MBIO N/A
- P/E Ratio
- SPHL N/A
- MBIO N/A
- Revenue Growth
- SPHL N/A
- MBIO N/A
- 52 Week Low
- SPHL $0.35
- MBIO $0.89
- 52 Week High
- SPHL $7.80
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- SPHL 55.63
- MBIO 42.51
- Support Level
- SPHL $0.49
- MBIO $1.43
- Resistance Level
- SPHL $0.70
- MBIO $1.69
- Average True Range (ATR)
- SPHL 0.09
- MBIO 0.10
- MACD
- SPHL 0.00
- MBIO -0.01
- Stochastic Oscillator
- SPHL 44.44
- MBIO 11.75
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation. The company operates and manages its business as a single segment - in the development of construction projects. It derives maximum revenue from its Residential Customers.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.